Form 4: Elite Pharmaceuticals EVP Exercises 2.5 Million Stock Options

Douglas Plassche, Executive Vice President of Operations at Elite Pharmaceuticals Inc., exercised 2.5 million stock options at $0.03 per share, increasing his direct beneficial ownership of common stock.

Summary

• Douglas Plassche, Executive Vice President of Operations at Elite Pharmaceuticals Inc. (ELTP), exercised 2,500,000 stock options.
• The transaction occurred on July 3, 2025.
• The exercise price for these options was $0.03 per share.
• Following this transaction, Douglas Plassche directly beneficially owns 2,500,000 shares of common stock.
• He also continues to hold 5,000,000 derivative securities (stock options) with an exercise price of $0.03, which became fully vested and exercisable as of January 3, 2025, and are set to expire on January 3, 2033.

Sentiment

Score: 7

Explanation: The exercise of a significant number of stock options by a key executive generally indicates confidence in the company's future, as the executive is converting options into shares, suggesting a belief in potential appreciation. This is a positive signal, though the document itself is purely transactional and does not provide operational or financial performance details.

Positives

• The exercise of a significant number of stock options by a key executive indicates confidence in the company's future prospects.
• The options were fully vested and exercisable, suggesting a mature grant or accelerated vesting, allowing the executive to convert potential value into direct equity ownership.

Future Outlook

The document, a Form 4, primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

Insider transactions, such as option exercises, are common in the pharmaceutical industry as a form of executive compensation and can signal management's belief in the company's long-term value, particularly for development-stage or smaller companies like Elite Pharmaceuticals where such exercises might precede significant milestones or product developments.

Comparison to Industry Standards

• This Form 4 reports a standard executive stock option exercise. The exercise price of $0.03 is specific to Elite Pharmaceuticals' compensation structure and stock valuation at the time of grant.
• Without specific details on the original grant terms or the company's current stock price, a direct comparison to industry-wide executive compensation benchmarks or specific peer companies like Teva Pharmaceutical Industries Ltd. or Viatris Inc. is not directly derivable from this document.
• However, the exercise of a large block of options at a low strike price is a common feature of long-term incentive plans across various industries, including pharmaceuticals, designed to align executive interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The exercise of options by an executive can be viewed positively as it aligns management's interests with shareholders and signals confidence in the company's future value.
• Employees: No direct impact on general employees is indicated by this transaction.

Key Dates

Keywords

Elite Pharmaceuticals, ELTP, Stock Options, Insider Transaction, Form 4, Beneficial Ownership, Executive Compensation, Douglas Plassche